You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

Drugs in MeSH Category Radiation-Sensitizing Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Inforlife METRONIDAZOLE IN PLASTIC CONTAINER metronidazole INJECTABLE;INJECTION 206191-001 Feb 25, 2019 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Chartwell Rx METRONIDAZOLE metronidazole GEL;TOPICAL 090903-001 Jul 22, 2011 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Torrent DIMETHYL FUMARATE dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 210390-002 Jan 6, 2025 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Rising METRONIDAZOLE IN PLASTIC CONTAINER metronidazole INJECTABLE;INJECTION 205531-001 May 9, 2017 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Sola Pharms DIMETHYL FUMARATE dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 210436-001 Mar 26, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Superpharm METRONIDAZOLE metronidazole TABLET;ORAL 070009-001 Dec 11, 1984 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Accord Hlthcare CISPLATIN cisplatin INJECTABLE;INJECTION 206774-001 Aug 18, 2015 AP RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Radiation-Sensitizing Agents Market Analysis and Financial Projection

The global market for radiation-sensitizing agents is experiencing robust growth driven by rising cancer prevalence and technological innovations, while the patent landscape reflects intense R&D activity and strategic IP protections. Below is a detailed analysis:


Market Dynamics

Growth Drivers

  • Rising Cancer Burden: With ~19.3M global cancer cases in 2020 (WHO)[3], radiosensitizers are critical for enhancing radiotherapy efficacy. The market is projected to reach USD 4.8B by 2030 (CAGR 9.2%)[5] or USD 3.5B by 2033 (CAGR 12.5%)[7], varying by report scope.
  • Technological Advancements: Innovations include nanoparticle-based agents (e.g., Abraxane[2]) for targeted delivery, combination therapies with immunotherapy[1][7], and precision medicine approaches[3].
  • Regulatory Support: Agencies are streamlining approvals for novel radiosensitizers, such as the FDA’s accelerated pathway for oncology drugs[12].

Regional Insights

  • North America dominates due to advanced healthcare infrastructure and significant R&D investments (e.g., USD 6.56B U.S. cancer research funding in 2021)[3].
  • Asia-Pacific is emerging rapidly, with China and India increasing healthcare spending and adopting advanced therapies[1].

Key Trends

  • Combination Therapies: Integration with immunotherapy and targeted drugs to improve outcomes[1][7].
  • Nanotechnology: Nanoparticles enhance tumor targeting and reduce off-target toxicity, exemplified by Abraxane (nanoparticle albumin-bound paclitaxel)[2][6].
  • Supergenerics: Reformulations of legacy drugs (e.g., Xyotax[2]) are competing with branded agents post-patent expiration.

Patent Landscape

Innovations and Key Players

  • Novel Compounds: Patents cover nitro-5deazaflavin derivatives (JP2000212087A)[11], non-platinum-based radiosensitizers (CA2895526A1)[18], and cerium oxide nanoparticles for reducing radiation side effects (BioCurity)[14].
  • Targeted Therapies: Shuttle Pharmaceuticals holds patents for HDAC inhibitors and formulations like ropidoxuridine, improving drug bioavailability[10].
  • Alpha-Particle Radiopharmaceuticals: Research on 225Ac-based therapies targets bone metastases with high cytotoxicity[4].

Challenges

  • Patent Expirations: Older drugs like Taxol face competition from generics and supergenerics[2]. For example, 6/7 top cytotoxic drugs lost U.S. exclusivity by 2011[2].
  • Regulatory Hurdles: Repurposed drugs require new patents for novel indications, complicating ROI for companies[12]. Only 50% of NIH SBIR-funded radiosensitizers reach clinical trials[13].

Strategic Moves

  • Collaborations: Academia-industry partnerships accelerate clinical translation (e.g., Wake Forest’s 225Ac research[4]).
  • Lifecycle Management: Companies like Aventis aggressively market drugs like Taxotere to counter generics[2].

Future Outlook

  • Market Expansion: Asia-Pacific’s healthcare investments and North America’s R&D leadership will sustain growth. Combination therapies and nanotechnology remain focal points.
  • IP Strategies: Expect increased filings for nanoparticle formulations and targeted agents. Legal battles over generics and supergenerics may intensify[2][12].
  • Regulatory Evolution: Adaptive pathways and global harmonization efforts could streamline approvals for repurposed drugs[12].

"The future of radiosensitizers lies in multi-modal approaches that marry precision medicine with patient safety." – Industry Analyst[1]


Key Takeaways

  1. The radiosensitizer market is growing at 7–12.5% CAGR, driven by cancer prevalence and innovation.
  2. Patent portfolios focus on nanotechnology, combination therapies, and reduced toxicity.
  3. Generics and regulatory complexity challenge legacy drugs, while collaborations fuel next-gen agents.

FAQs
Q1: Which regions lead in radiosensitizer adoption?
A: North America dominates, but Asia-Pacific is rising due to healthcare modernization.

Q2: How do nanoparticles improve radiosensitizers?
A: They enhance tumor targeting and reduce damage to healthy tissues[6][14].

Q3: What are supergenerics?
A: Reformulated drugs (e.g., Abraxane) offering clinical advantages over generic equivalents[2].

Q4: How long do radiosensitizer patents typically last?
A: Variable, but key patents (e.g., BioCurity’s cerium oxide tech) have terms extending to 2023–2040[10][14].

Q5: What role do regulators play?
A: They expedite approvals for promising agents but face challenges in global harmonization[12][13].


Sources cited: [1][2][3][4][6][7][10][12][13][14]

References

  1. https://pmarketresearch.com/product/worldwide-disperse-dyestuff-market-research-2024-by-type-application-participants-and-countries-forecast-to-2030/worldwide-radiosensitizer-market-research-2024-by-type-application-participants-and-countries-forecast-to-2030
  2. https://www.ufrgs.br/imunovet/molecular_immunology/anticancer.html
  3. https://www.verifiedmarketreports.com/product/radiosensitizer-market/
  4. https://apps.dtic.mil/sti/trecms/pdf/AD1177557.pdf
  5. https://sites.google.com/view/beaconconsultinggroup/top-industry-reports/radiosensitizer-market-by-application
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4816444/
  7. https://www.imarcgroup.com/radiosensitizer-market
  8. https://sites.google.com/view/growth-grid/home/seo-optimization/us-radiosensitizer-market-how-demographic-changes-are-impacting-demand
  9. https://core.ac.uk/download/pdf/232571867.pdf
  10. https://shuttlepharma.com/wp-content/uploads/2024/03/Shuttle-Pharma-Investor-Presentation-February-2024.pdf
  11. https://patents.google.com/patent/JP2000212087A/en
  12. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1400029/full
  13. https://pubmed.ncbi.nlm.nih.gov/32216707/
  14. https://www.businesswire.com/news/home/20220310005091/en/BioCurity-Pharmaceuticals-Inc.-BioCurity-or-Company-Expanding-Patent-Portfolio-Successes-for-Supportive-Cancer-Drugs-Designed-to-Prevent-Radiation-Therapy-Side-Effects
  15. https://core.ac.uk/download/pdf/219378331.pdf
  16. https://patents.google.com/patent/EP0270292A3/en
  17. https://pubmed.ncbi.nlm.nih.gov/1531214/
  18. https://patents.google.com/patent/CA2895526A1/en
Last updated: 2025-03-27

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.